Intestinal Research

Volume 17(4); October 2019

Editorial

IBD

Tacrolimus in pediatric ulcerative colitis: does it have a role?: Seung Kim; Intest Res 2019;17(4):441-442. Published online October 28, 2019; DOI: https://doi.org/10.5217/ir.2019.00124

PDF PubReader ePub

4,889 View
109 Download

Focused Reviews

Microbiota

Importance of nutritional therapy in the management of intestinal diseases: beyond energy and nutrient supply: Seong-Eun Kim; Intest Res 2019;17(4):443-454. Published online September 4, 2019; DOI: https://doi.org/10.5217/ir.2019.00075

Abstract PDF PubReader ePub

The gut is an immune-microbiome-epithelial complex. Gut microbiome-host interactions have widespread biological implications, and the role of this complex system extends beyond the digestion of food and nutrient absorption. Dietary nutrients can affect this complex and play a key role in determining gut homeostasis to maintain host health. In this article, we review various dietary nutrients and their contribution to the pathogenesis and treatment of various intestinal diseases including inflammatory bowel disease, irritable bowel syndrome, colorectal cancer, and diverticulitis, among other such disorders. A better understanding of diet-host-gut microbiome interactions is essential to provide beneficial nutrients for gut health and to limit nutritional hazards to ensure successful nutritional management of gastrointestinal conditions in clinical practice.

Citations

Citations to this article as recorded by

Capsule robots for the monitoring, diagnosis, and treatment of intestinal diseases
Xiangyu Wei, Peipei Xi, Minjie Chen, Ya Wen, Hao Wu, Li Wang, Yujuan Zhu, Yile Ren, Zhifeng Gu
Materials Today Bio.2024; 29: 101294. CrossRef
TOPICAL ISSUES OF NUTRITION OF PATIENTS WITH DISEASES OF THE GASTROINTESTINAL TRACT
Nikishina S.S.
"Medical & pharmaceutical journal "Pulse".2023; : 17. CrossRef
An Asian perspective on irritable bowel syndrome
Kee Wook Jung, Seung-Jae Myung
Intestinal Research.2023; 21(2): 189. CrossRef
Rectal swabs are a reliable method of assessing the colonic microbiome
Greg Turner, Michael O’Grady, Daniel Hudson, Xochitl Morgan, Frank Frizelle, Rachel Purcell
International Journal of Medical Microbiology.2022; 312(2): 151549. CrossRef
Detection of Colistin Sulfate on Piglet Gastrointestinal Tract Microbiome Alterations
Shulin Fu, Yuzhen Yuan, Xinyue Tian, Linglu Zhou, Ling Guo, Dan Zhang, Jing He, Chun Peng, Yinsheng Qiu, Chun Ye, Yu Liu, Bingbing Zong
Veterinary Sciences.2022; 9(12): 666. CrossRef
The Clinical Features of Inflammatory Bowel Disease in Patients with Obesity
Seong Kyun Kim, Ho-Su Lee, Beom-Jun Kim, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park, Masanao Nakamura
Canadian Journal of Gastroenterology and Hepatology.2021; 2021: 1. CrossRef
EFFECTS OF ADOLESCENTS' NUTRITION ON THEIR QUALITY OF LIFE
Filina I.A., Nikishina S.S., Kulakova A.S.
"Medical & pharmaceutical journal "Pulse".2021; : 13. CrossRef
Faecal Microbiota Microsphere Contributed to Relieving Gut Barrier Damage in Colitis
Shuang Zhen, Cheng Zhao, Xin Zhao, Wu Ji, Jieshou Li
Macromolecular Research.2020; 28(6): 644. CrossRef
Dysregulation of gut microbiome is linked to disease activity of rheumatic diseases
Yanfeng Bao, Chen Dong, Juan Ji, Zhifeng Gu
Clinical Rheumatology.2020; 39(9): 2523. CrossRef

9,504 View
407 Download
8 Web of Science
9 Crossref

Colorectal neoplasia

Nutritional issues in patients with cancer: Duk Hwan Kim; Intest Res 2019;17(4):455-462. Published online October 14, 2019; DOI: https://doi.org/10.5217/ir.2019.00076

Abstract PDF PubReader ePub

Cancer is a catabolic inflammatory disease that causes patients to often experience weight loss, or even cachexia in severe cases. Undernourishment in patients with cancer impairs the quality of life and therapeutic response, further leading to poor prognosis. Active and frequent nutritional screening and assessment using valid tools are important for fast and appropriate nutritional intervention. Additionally, a suitable individualized nutritional intervention strategy should be established based on the nutritional assessment result. In general, nutritional intervention begins with nutritional counseling of patients diagnosed with cancer, and a well-planned nutritional counseling improves the treatment adherence and nutritional status. When planning nutritional supplementation for cancer patients, specific nutrients, including amino acids and fatty acids, should be considered. However, there has been no consistent result showing that any particular nutrient significantly improves the prognosis of cancer patients. Hence, continuous attention from clinical physicians is needed to plan nutritional improvement in patients with cancer.

Citations

Citations to this article as recorded by

Experiences of cancer patients in receiving dietary advice from healthcare professionals and of healthcare professionals in providing this advice—a systematic review
Laura Keaver, Niamh O’Callaghan, Amy E. LaVertu, Cherith J. Semple, Ciara M. Hughes, Jeffrey R. Hanna, Lisa Ryan
Journal of Cancer Survivorship.2024; 18(4): 1211. CrossRef
Validation and modification of simplified Geriatric Assessment and Elderly Prognostic Index: Effective tools for older patients with diffuse large B‐cell lymphoma
Xiaoya Yun, Jiefei Bai, Ru Feng, Jiangtao Li, Ting Wang, Yazi Yang, Jingjing Yin, Long Qian, Shuai Zhang, Qingyun Cao, Xiaoxuan Xue, Hongmei Jing, Hui Liu
Cancer Medicine.2024;[Epub] CrossRef
Demographic, clinical and psychological predictors of malnutrition among people with liver cancer
Yumi Kim, Sung Reul Kim, Kyounghae Kim, Su Jong Yu
European Journal of Oncology Nursing.2024; 68: 102497. CrossRef
Examining the relationship between nutritional status and wound healing in head and neck cancer treatment: A focus on malnutrition and nutrient deficiencies
Yajun Chen, Yuying Li, Yaqi Ceng, Chunlei Li, Yueying Li, Yujie Wang, Kun Wang
International Wound Journal.2024;[Epub] CrossRef
Anti-breast cancer activity of the essential oil from grapefruit mint (Mentha suaveolens × piperita)
Zohreh Jahanafrooz, Mir Mohammad Hossein Mousavi, Soghra Akbarzadeh, Maedeh Hemmatzadeh, Filippo Maggi, Mohammad Reza Morshedloo
Fitoterapia.2024; 174: 105875. CrossRef
Accompagnement alimentaire du cancéreux, lutte contre les dégoûts et aversions
Philippe Pouillart
Pratiques en nutrition.2024; 20(78): 14. CrossRef
Exome-Based Amino Acid Optimization: A Dietary Strategy to Satisfy Human Nutritional Demands and Enhance Muscle Strength in Breast Tumor Mice Undergoing Chemotherapy
Congcong Gong, Chunwei Jiao, Huijia Liang, Yuxin Ma, Qingping Wu, Yizhen Xie
Journal of Agricultural and Food Chemistry.2024; 72(13): 7089. CrossRef
Prehabilitation and its Outcomes in Cancer Patients: A Narrative Review
A. J. Rajendran, M. A. Raja, S. Benedic Kingslin Suresh
Indian Journal of Physical Medicine and Rehabilitation.2024; 34(1): 5. CrossRef
Nutritional Experiences and Perceptions of Breast Cancer Patients Receiving Chemotherapy: A Qualitative Study
Sema Koçan, Canan Altınsoy, Yağmur Demirel Özbek
Ordu Üniversitesi Hemşirelik Çalışmaları Dergisi.2024; 7(2): 358. CrossRef
Adopting a systems-thinking approach to optimise dietary and exercise referral practices for cancer survivors
Ria Joseph, Nicolas H. Hart, Natalie Bradford, Fiona Crawford-Williams, Matthew P. Wallen, Reegan Knowles, Chad Y. Han, Vivienne Milch, Justin J. Holland, Raymond J. Chan
Supportive Care in Cancer.2024;[Epub] CrossRef
Thoracic CT imaging in obesity: Technical challenges, imaging findings and future outlook
Perawish Suwathep, Alexander Sheeka, Susan Copley
Meta-Radiology.2024; 2(3): 100100. CrossRef
Evaluating the Outcomes in Patients with Colorectal Cancer Using the Malnutrition Universal Screening Tool: A Systematic Review
Calin Muntean, Andiana Roxana Blidari, Alaviana Monique Faur, Razvan Ovidiu Curca, Catalin Vladut Ionut Feier
Journal of Multidisciplinary Healthcare.2024; Volume 17: 4277. CrossRef
Poor nutrition doubles post-COVID-19 syndrome risk in cancer patients: insights from a Chinese multicentre study
Liangyuan Zhang, Haihang Yu, Jianzhou Yang, Rila Su, Jiaqi Zhang, Rongbiao Zeng, Yajie Liu, Lei Zhang, Junjie Xu
Frontiers in Nutrition.2024;[Epub] CrossRef
Effects of Five-Step Nutritional Interventions Conducted by a Multidisciplinary Care Team on Gastroenteric Cancer Patients Undergoing Chemotherapy: A Randomized Clinical Trial
Lijia Chen, Minyan Zhao, Liping Tan, Yusong Zhang
Nutrition and Cancer.2023; 75(1): 197. CrossRef
Effectiveness of mHealth diet interventions in cancer survivors: A systematic review and meta-analysis of randomized controlled trials
Yabo Gong, Xiaohan Jiang, Xijie Chen, Shi Chen, Yuee Wen, Xiuhong Yuan, Jiamin Chen, Junsheng Peng
Asia-Pacific Journal of Oncology Nursing.2023; 10(3): 100196. CrossRef
Mapping the global research landscape on nutritional support for patients with gastrointestinal malignancy: visualization analysis
Muna Shakhshir, Amani S. Abushanab, Amer Koni, Abdelkarim Barqawi, Khaled Demyati, Samah W. Al-Jabi, Sa’ed H. Zyoud
Supportive Care in Cancer.2023;[Epub] CrossRef
Prognostic significance of controlling nutritional status score for patients with gastric cancer: A systematic review and meta‑analysis
Jian Yin, Jin Qu, Xiaoxiao Liang, Meimei Wang
Experimental and Therapeutic Medicine.2023;[Epub] CrossRef
Web-based nutrition: a useful resource for cancer patients?
Diana Elena Lazar, Roxana Postolica, Bianca Hanganu, Veronica Mocanu, Beatrice Gabriela Ioan
Frontiers in Nutrition.2023;[Epub] CrossRef
Depression and Anxiety Mediate the Associations between Nutritional Status, Functional Capacity, and Quality of Life in Patients with Cancer
Iliana Evangelou, Konstantina Vamvakari, Ioanna Panagiota Kalafati, Michail Kipouros, Arezina N. Kasti, Rena I. Kosti, Fotini Bonoti, Odysseas Androutsos
Nutrition and Cancer.2023; 75(9): 1783. CrossRef
Expert design thinking workshops to analyze users’ perceived applicability of NUTRI-ONCOCARE algorithm to prevent and treat malnutrition in cancer patients under routine clinical practice conditions in Spain: the ALLIANCE study
Enrique Grande, Fernando Moreno, José Trigo, Jaume Capdevila, Jimena Abilés, Mariola Sirvent, Margarita Garrido-Siles, Gabriel Olveira, Julia Ocón, Maria Luisa Fernández Soto
Supportive Care in Cancer.2023;[Epub] CrossRef
Anti-Cancer Properties of Flaxseed Proteome
Yulia Merkher, Elizaveta Kontareva, Anastasia Alexandrova, Rajesha Javaraiah, Margarita Pustovalova, Sergey Leonov
Proteomes.2023; 11(4): 37. CrossRef
Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors
Salvatore Artale, Sabrina Barzaghi, Nunziata Grillo, Claudia Maggi, Stefano Lepori, Chiara Butti, Antonella Bovio, Lucia Barbarini, Andrea Colombo, Laura Zanlorenzi, Elena Castiglioni, Alessandra Trojani
Nutrition and Cancer.2022; 74(1): 2. CrossRef
Chronic Inflammation in Obesity and Cancer Cachexia
Rosa Divella, Gennaro Gadaleta Caldarola, Antonio Mazzocca
Journal of Clinical Medicine.2022; 11(8): 2191. CrossRef
A Nutrition and Inflammation-Related Nomogram to Predict Overall Survival in Surgically Resected Esophageal Squamous Cell Carcinoma (ESCC) Patients
Juan Li, Xinyu Mei, Di Sun, Mingfa Guo, Mingran Xie, Xia Chen
Nutrition and Cancer.2022; 74(5): 1625. CrossRef
Diet and exercise advice and referrals for cancer survivors: an integrative review of medical and nursing perspectives
Ria Joseph, Nicolas H. Hart, Natalie Bradford, Oluwaseyifunmi Andi Agbejule, Bogda Koczwara, Alexandre Chan, Matthew P. Wallen, Raymond J. Chan
Supportive Care in Cancer.2022; 30(10): 8429. CrossRef
MicroRNAs: Novel players in the diagnosis and treatment of cancer cachexia (Review)
Xin Li, Lidong Du, Qiang Liu, Zhong Lu
Experimental and Therapeutic Medicine.2022;[Epub] CrossRef
Nutritional risk screening in malignant tumors: a study of 375 cancer inpatients
Min Zhang, Yuying Guo, Xiaodi Zhang, Yu Zhang, Yuanyuan Fan, Yanting Liu, Kelei Zhao, Ruijuan Fan, Ping Lu
Supportive Care in Cancer.2022; 30(10): 8333. CrossRef
Prognostic Value of the Pre-Treatment Prognostic Nutritional Index for Patients with Unresectable Locally-Advanced and Advanced Stage Upper Gastrointestinal Tract Cancer
Chaichana Chantharakhit, Nantapa Sujaritvanichpong, Chanachai Chantharakhit
International Journal of General Medicine.2022; Volume 15: 6681. CrossRef
Visceral fat area and albumin based nutrition-related prognostic index model could better stratify the prognosis of diffuse large B-cell lymphoma in rituximab era
Ziyuan Shen, Lingling Hu, Shuo Zhang, Qian Sun, Weidong Li, Dongmei Yan, Guoqi Cai, Wei Sang
Frontiers in Nutrition.2022;[Epub] CrossRef
Malnutrition induced by cancer and oncology treatment
Jelena Kostadinović, Jelena Kotur-Stevuljević, Nevena Ivanović, Zoran Andrić
Hrana i ishrana.2022; 63(1): 9. CrossRef
Irish cancer patients and survivors have a positive view of the role of nutritional care in cancer management from diagnosis through survivorship
Laura Keaver
Irish Journal of Medical Science (1971 -).2021; 190(4): 1387. CrossRef
Nutrition intervention is beneficial to the quality of life of patients with gastrointestinal cancer undergoing chemotherapy in Vietnam
Linh Thuy Nguyen, Anh Kim Dang, Phuong Thi Duong, Hanh Bich Thi Phan, Chinh Tuyet Thi Pham, Anh Tuan Le Nguyen, Huong Thi Le
Cancer Medicine.2021; 10(5): 1668. CrossRef
Managing the effects of cancer and cancer treatments on patients’ nutritional status
Kathell Margaret Geraghty
Nursing Standard.2021; 36(3): 54. CrossRef
Overcoming Disparities in Cancer: A Need for Meaningful Reform for Hispanic and Latino Cancer Survivors
Joshua P. Kronenfeld, Kristi D. Graves, Frank J. Penedo, Betina Yanez
The Oncologist.2021; 26(6): 443. CrossRef
Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in Cancer Patients?
Dana A. M. Mustafa, Lawlaw Saida, Diba Latifi, Leonoor V. Wismans, Willem de Koning, Lona Zeneyedpour, Theo M. Luider, Bernadette van den Hoogen, Casper H. J. van Eijck
Cancers.2021; 13(12): 2896. CrossRef
Detection of Lung Cancer via Blood Plasma and 1H-NMR Metabolomics: Validation by a Semi-Targeted and Quantitative Approach Using a Protein-Binding Competitor
Elien Derveaux, Michiel Thomeer, Liesbet Mesotten, Gunter Reekmans, Peter Adriaensens
Metabolites.2021; 11(8): 537. CrossRef
Short Nutritional Assessment Questionnaire as a predictor of undernutrition in cancer patients receiving outpatient chemotherapy: A retrospective study
Kiyomi Harada, Masami Okagaki, Hiroko Neriya, Kengo Yoshii, Keiko Sekido, Akane Higashi
European Journal of Oncology Nursing.2021; 54: 102013. CrossRef
A Quasi-Experimental Study of the Effect of Ginger Tea on Preventing Nausea and Vomiting in Patients With Gynecological Cancers Receiving Cisplatin-Based Regimens
Dhuha Y. Wazqar, Hala A. Thabet, Amany M. Safwat
Cancer Nursing.2021; 44(6): E513. CrossRef
Quality of Life of Cancer Patients Receiving Enteral Nutrition: A Systematic Review of Randomized Controlled Trials
Elwira Gliwska, Dominika Guzek, Zuzanna Przekop, Jacek Sobocki, Dominika Głąbska
Nutrients.2021; 13(12): 4551. CrossRef
Nutritional Status of Patients with Nasopharyngeal Carcinoma
Yussy Afriani Dewi, Arief Fakhrizal, Shinta Fitri Boesoirie, Ayu Hardianti Saputri
Open Access Macedonian Journal of Medical Sciences.2021; 9(B): 1435. CrossRef
Bilayer Mucoadhesive Buccal Film for Mucosal Ulcers Treatment: Development, Characterization, and Single Study Case
Thais F. R. Alves, Alesssandra C. Rios, Katiusca da Silva Pontes, Decio L. Portella, Norberto Aranha, Patricia Severino, Eliana B. Souto, Joyce K. M. Gonsalves, Rogeria de Souza Nunes, Marco V. Chaud
Pharmaceutics.2020; 12(7): 657. CrossRef
A Study on Challenges to Health Care Delivery Faced by Cancer Patients in India During the COVID-19 Pandemic
Manasij Mitra, Maitraye Basu
Journal of Primary Care & Community Health.2020;[Epub] CrossRef
Enteral feed based gradual improvement of body mass index and normalization of micronutrients in children with malnutrition
Meryem KEÇELİ BAŞARAN, Nur ZENGIN, Ali DOĞAN, Alihan SURSAL, Fatih OZDENER
Journal of Surgery and Medicine.2020; 4(9): 826. CrossRef
Quality of Life (QoL) of cancer patients and its association with nutritional and performance status: A pilot study
Mohammad Morshad Alam, Tania Rahman, Zinia Afroz, Promit Ananyo Chakraborty, Abrar Wahab, Sanjana Zaman, Mohammad Delwer Hossain Hawlader
Heliyon.2020; 6(10): e05250. CrossRef
Altered Preoperative Nutritional Status in Colorectal Cancer: A Not So Infrequent Issue
Javier Páramo-Zunzunegui, Araceli Ramos-Carrasco, Marcos Alonso-García, Rosa Cuberes-Montserrat, Gil Rodríguez-Caravaca, Manuel Durán-Poveda, María Ximena Silveyra
Journal of Nutrition and Metabolism.2020; 2020: 1. CrossRef
Impact of Early Incorporation of Nutrition Interventions as a Component of Cancer Therapy in Adults: A Review
Julie Richards, Mary Beth Arensberg, Sara Thomas, Kirk W. Kerr, Refaat Hegazi, Michael Bastasch
Nutrients.2020; 12(11): 3403. CrossRef

9,235 View
375 Download
42 Web of Science
46 Crossref

IBD

Nutritional approach as therapeutic manipulation in inflammatory bowel disease: Jin Young Yoon; Intest Res 2019;17(4):463-475. Published online October 28, 2019; DOI: https://doi.org/10.5217/ir.2019.00078

Abstract PDF PubReader ePub

Malnutrition is observed more frequently in patients with inflammatory bowel disease (IBD) than in the general population and associated with adverse clinical outcomes. This study aimed to review the current knowledge regarding the efficacy of dietary and nutritional intervention in IBD patients. Exclusive enteral nutrition might be inferior to corticosteroid treatment in adults with active Crohn’s disease (CD) but might even be superior considering the adverse effects of corticosteroid treatment in children. Total parenteral nutrition has no advantage over enteral nutrition, which is considered a more physiologic modality in organ function. Current guidelines do not yet recommend ω3-polyunsaturated fatty acid supplementation for the prevention and maintenance of remission in IBD patients. Dietary fiber supplementation could be effective in the relief of symptoms and maintenance of remission in ulcerative colitis (UC). Although vitamin D may be favorable to clinical course of IBD and bone density. Probiotic supplementation has proven to be effective in preventing and treating pouchitis for UC but is less effective in treating CD. Nutritional interventions not only correct nutritional deficiencies but also improve symptoms and clinical courses of the disease. Hence, nutritional approaches need to be developed to significantly evaluate the effectiveness of dietary interventions used to treat IBD.

Citations

Citations to this article as recorded by

Parenteral Nutrition, Inflammatory Bowel Disease, and Gut Barrier: An Intricate Plot
Carlo Covello, Guia Becherucci, Federica Di Vincenzo, Angelo Del Gaudio, Marco Pizzoferrato, Giovanni Cammarota, Antonio Gasbarrini, Franco Scaldaferri, Maria Chiara Mentella
Nutrients.2024; 16(14): 2288. CrossRef
Association of selected adipokines with vitamin D deficiency in children with inflammatory bowel disease
Milos Geryk, Veronika Kucerova, Maria Velganova-Veghova, Hana Foltenova, Katerina Bouchalova, David Karasek, Martin Radvansky, Eva Karaskova
BMC Pediatrics.2024;[Epub] CrossRef
Self-reported food intolerance, dietary supplement use and malnutrition in chronic inflammatory bowel diseases: Findings from a cross-sectional study in Lebanon
Maha Hoteit, Nour Ftouni, Malak Olayan, Souheil Hallit, Joya Maria Karam, Mahmoud Hallal, Samer Hotayt, Bilal Hotayt, Imad Al Kassaa
PLOS ONE.2024; 19(7): e0305352. CrossRef
Leucine-Enriched Diet Reduces Fecal MPO but Does Not Protect Against DSS Colitis in a Mouse Model of Crohn’s Disease-like Ileitis
Drishtant Singh, Paola Menghini, Alexander Rodriguez-Palacios, Luca Di Martino, Fabio Cominelli, Abigail Raffner Basson
International Journal of Molecular Sciences.2024; 25(21): 11748. CrossRef
Improvement of ulcerative colitis control by searching and restricting of inflammatory trigger factors in daily clinical practice
Kun-Yu Tsai, Jeng-Fu You, Tzong-Yun Tsai, Yih Jong Chern, Yu-Jen Hsu, Shu-Huan Huang, Wen-Sy Tsai
Intestinal Research.2023; 21(1): 100. CrossRef
İnflamatuvar bağırsak hastalıklarında hastalığa özgü aktivite indeksinin depresyon ve inflamatuvar belirteçler ile ilişkisi
Büşra YÜKSEL, Sinem BAYRAM, Mehmet CİNDORUK, Harun KÜÇÜK
Akademik Gastroenteroloji Dergisi.2022; 21(1): 15. CrossRef
Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease
Seung Hyuk Kim, You Sun Kim, Si Hyeong Lee, Hyun Mi Lee, Won Eui Yoon, Seo Hyun Kim, Hee Jun Myung, Jeong Seop Moon
Intestinal Research.2022; 20(3): 321. CrossRef
COVID-19 and immunomodulation in IBD
Markus F Neurath
Gut.2020; 69(7): 1335. CrossRef

9,138 View
236 Download
8 Web of Science
8 Crossref

Original Articles

Inflammatory bowel diseases

Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan: Tadahiro Yanagi, Kosuke Ushijima, Hidenobu Koga, Takeshi Tomomasa, Hitoshi Tajiri, Reiko Kunisaki, Takashi Isihige, Hiroyuki Yamada, Katsuhiro Arai, Atsushi Yoden, Tomoki Aomatsu, Satoru Nagata, Keiichi Uchida, Yoshikazu Ohtsuka, Toshiaki Shimizu; Intest Res 2019;17(4):476-485. Published online August 31, 2019; DOI: https://doi.org/10.5217/ir.2019.00027

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Tacrolimus is effective for refractory ulcerative colitis in adults, while data for children is sparse. We aimed to evaluate the effectiveness and safety of tacrolimus for induction and maintenance therapy in Japanese children with ulcerative colitis.
Methods
We retrospectively reviewed the multicenter survey data of 67 patients with ulcerative colitis aged < 17 years treated with tacrolimus between 2000 and 2012. Patients’ characteristics, disease activity, Pediatric Ulcerative Colitis Activity Index (PUCAI) score, initial oral tacrolimus dose, short-term (2-week) and long-term (1-year) outcomes, steroid-sparing effects, and adverse events were evaluated. Clinical remission was defined as a PUCAI score < 10; treatment response was defined as a PUCAI score reduction of ≥ 20 points compared with baseline.
Results
Patients included 35 boys and 32 girls (median [interquartile range] at admission: 13 [11–15] years). Thirty-nine patients were steroid-dependent and 26 were steroidrefractory; 20 had severe colitis and 43 had moderate colitis. The initial tacrolimus dose was 0.09 mg/kg/day (range, 0.05–0.12 mg/kg/day). The short-term clinical remission rate was 47.8%, and the clinical response rate was 37.3%. The mean prednisolone dose was reduced from 19.2 mg/day at tacrolimus initiation to 5.7 mg/day at week 8 (P< 0.001). The adverse event rate was 53.7%; 6 patients required discontinuation of tacrolimus therapy.
Conclusions
Tacrolimus was a safe and effective second-line induction therapy for steroid-dependent and steroid-refractory ulcerative colitis in Japanese children.

Citations

Citations to this article as recorded by

Real‐world effectiveness of ustekinumab and vedolizumab in TNF‐exposed pediatric patients with ulcerative colitis
Perseus V. Patel, Amy Zhang, Balu Bhasuran, Vignesh G. Ravindranath, Melvin B. Heyman, Sofia G. Verstraete, Atul J. Butte, Michael J. Rosen, Vivek A. Rudrapatna
Journal of Pediatric Gastroenterology and Nutrition.2024; 78(5): 1126. CrossRef
Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
Journal of Gastroenterology and Hepatology.2023; 38(4): 523. CrossRef
Clinical outcome of ulcerative colitis with severe onset in children: a multicenter prospective cohort study
Ryusuke Nambu, Katsuhiro Arai, Takahiro Kudo, Takatsugu Murakoshi, Reiko Kunisaki, Tatsuki Mizuochi, Sawako Kato, Hideki Kumagai, Mikihiro Inoue, Takashi Ishige, Takeshi Saito, Atsuko Noguchi, Toshifumi Yodoshi, Shin-Ichiro Hagiwara, Naomi Iwata, Shigeo N
Journal of Gastroenterology.2023; 58(5): 472. CrossRef
Oral Tacrolimus in Steroid Refractory and Dependent Pediatric Ulcerative Colitis—A Systematic Review and Meta-Analysis
Rishi Bolia, Akhil Goel, Pooja Semwal, Anshu Srivastava
Journal of Pediatric Gastroenterology & Nutrition.2023; 77(2): 228. CrossRef
Tacrolimus as an alternative treatment for patients with juvenile idiopathic arthritis
Susumu Yamazaki, Masaki Shimizu, Yuko Akutsu, Asami Shimbo, Masaaki Mori
Modern Rheumatology.2022; 32(4): 783. CrossRef
3D printed tacrolimus suppositories for the treatment of ulcerative colitis
Iria Seoane-Viaño, Jun Jie Ong, Asteria Luzardo-Álvarez, Miguel González-Barcia, Abdul W. Basit, Francisco J. Otero-Espinar, Alvaro Goyanes
Asian Journal of Pharmaceutical Sciences.2021; 16(1): 110. CrossRef
Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
You Sun Kim
Intestinal Research.2021; 19(4): 357. CrossRef
Tacrolimus in pediatric ulcerative colitis: does it have a role?
Seung Kim
Intestinal Research.2019; 17(4): 441. CrossRef

13,629 View
235 Download
10 Web of Science
8 Crossref

Inflammatory bowel diseases

Familial aggregation of inflammatory bowel disease in India: prevalence, risks and impact on disease behavior: Rupa Banerjee, Partha Pal, Susan Hutfless, B Girish Ganesh, D Nageshwar Reddy; Intest Res 2019;17(4):486-495. Published online August 6, 2019; DOI: https://doi.org/10.5217/ir.2018.00174

Abstract PDF PubReader ePub

Background/Aims
Information about familial aggregation of inflammatory bowel disease (IBD) in Asia is limited. We aimed to analyze the prevalence and risk of familial IBD in an Indian cohort and compare familial and sporadic cases.
Methods
Familial IBD cases were identified from a large prospectively maintained IBD registry. The prevalence of IBD in first- and seconddegree relatives of index cases was evaluated. The disease behavior was compared to that of sporadic cases.
Results
Total 3,553 patients (ulcerative colitis [UC], 2,053; Crohn’s disease [CD], 1,500) were included. Familial IBD was noted in 4.13% of CD and 4.34% of UC patients. Family history was commoner in pediatric group (< 18 years) (P= 0.0002; odds ratio [OR], 2.8; 95% confidence interval [CI], 1.6–4.8). Majority had paternal transmission (UC, 67.42%; CD, 70.97%). Concordance of disease type was higher in UC (79.7%) compared to CD (37.1%). Familial IBD was associated with higher cumulative relapse rate (CD, P< 0.001; UC, P< 0.001), higher cumulative rate of surgery (CD, P< 0.001; UC, P< 0.001) and higher rate of biologic use (CD, P= 0.010; UC, P= 0.015). Pan-colitis was higher in familial UC (P= 0.003; OR, 1.935; 95% CI, 1.248–3.000). Fistulizing disease was commoner in familial CD (P= 0.041; OR, 2.044; 95% CI, 1.030–4.056).
Conclusions
The prevalence of familial IBD in India appears comparable to rest of Asia but lower than the West. It is associated with a younger age of onset, higher incidence of pan-colitis in UC and fistulizing complications in CD. Familial IBD has higher cumulative relapse, surgery and biologic use rates. Hence, family history of IBD could have important prognostic implications.

Citations

Citations to this article as recorded by

Spectrum and trend of pediatric inflammatory bowel disease: A two-decade experience from northern India
Neelam Mohan, Shivani Deswal, Anubhuti Bhardwaj
Indian Journal of Gastroenterology.2024; 43(1): 208. CrossRef
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project
Carlos González-Muñoza, Margalida Calafat, Javier P Gisbert, Eva Iglesias, Miguel Mínguez, Beatriz Sicilia, Montserrat Aceituno, Fernando Gomollón, Xavier Calvet, Elena Ricart, Luisa De Castro, Montserrat Rivero, Francisco Mesonero, Lucía Márquez, Pilar N
Postgraduate Medical Journal.2024; 100(1189): 836. CrossRef
Differences of clinical phenotype between familial and sporadic Crohn’s disease in East China
Siyuan Dong, Xiaoxia Xiang, Yu Zhang, Rongbei Liu, Lingna Ye, Qian Cao
International Journal of Colorectal Disease.2024;[Epub] CrossRef
Inflammatory bowel disease in families with four or more affected first-degree relatives
Elad Boaz, Ariella Bar-Gil Shitrit, Menachem Schechter, Eran Goldin, Petachia Reissman, Shlomo Yellinek, Benjamin Koslowsky
Scandinavian Journal of Gastroenterology.2023; 58(1): 20. CrossRef
Clinical Phenotype and Disease Course of Inflammatory Bowel Disease: A Comparison Between Sporadic and Familial Cases
Bahar Saberzadeh-Ardestani, Amir Anushiravani, Fariborz Mansour-Ghanaei, Hafez Fakheri, Homayoon Vahedi, Farshad Sheikhesmaeili, Abbas Yazdanbod, Seyed Hamid Moosavy, Hasan Vosoghinia, Iradj Maleki, Siavosh Nasseri-Moghaddam, Bardia Khosravi, Masoud Malek
Inflammatory Bowel Diseases.2022; 28(7): 1004. CrossRef
Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South‐East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease‐Emerging Nations' Consortium
Rupa Banerjee, Partha Pal, Ida Hilmi, Uday C Ghoshal, Devendra C Desai, Mohammed Masudur Rahman, Usha Dutta, Syed A Mohiuddin, Munnera Al Mohannadi, Mathew Philip, Ganesh N Ramesh, Madunil A Niriella, Arjuna P De Silva, Hithanadura Janaka de Silva, Pises
Journal of Gastroenterology and Hepatology.2022; 37(6): 1004. CrossRef
Does the road to primary prevention of inflammatory bowel disease start from childhood?
Saurabh Kedia, Vineet Ahuja
JGH Open.2022; 6(6): 365. CrossRef
What Are the Different Phenotypes of Inflammatory Bowel Disease in Asia?
Su Bee Park, Jin Young Yoon, Jae Myung Cha
Gut and Liver.2022; 16(5): 676. CrossRef
Phenotypic Pattern of Early Versus Later-Onset Pediatric Inflammatory Bowel Disease in a Eurasian Country
Bilge S. Akkelle, Deniz Ertem, Burcu Volkan, Engin Tutar
Journal of Pediatric Gastroenterology & Nutrition.2022; 75(4): e61. CrossRef
Following the Indian Immigrant: adoption of westernization results in a western gut microbiome and an increased risk of inflammatory bowel diseases
Leah D D'Aloisio, Vignesh Shetty, Mamatha Ballal, Deanna L Gibson
FEMS Microbiology Ecology.2022;[Epub] CrossRef
Inflammatory bowel disease in India: challenges and opportunities
Alice Snell, Jonathan Segal, Jimmy Limdi, Rupa Banerjee
Frontline Gastroenterology.2021; 12(5): 390. CrossRef
Epidemiology and diagnosis of inflammatory bowel diseases
Kang-Moon Lee
Journal of the Korean Medical Association.2021; 64(9): 579. CrossRef
Impact of Demographic, Clinical and Psychosocial Variables on Drug Adherence and Outcomes in Indian Patients With Inflammatory Bowel Disease
Rupa Banerjee, Partha Pal, Bhargavi Adigopula, Duvvuru Nageshwar Reddy
Journal of Clinical Gastroenterology.2021; 55(10): e92. CrossRef
Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, Upender Shava, Girish Ganesh, D. Nageshwar Reddy
Intestinal Research.2021; 19(4): 398. CrossRef
Inflammatory bowel diseases in Tamil Nadu: A survey of demographics, clinical profile, and practices
Rohan V Yewale, Kartik Natarajan, Jeyaraj Ubal Dhus, Sarojini Ashok Parameswaran, Kallipatti Ramaswamy Palaniswamy, Doraisamy Babu Vinish, Aravindh Somasundaram, Arulraj Ramakrishnan, Sibithooran Karmegam, Ramaswamy Saraswathy Arun, Ujjani Shankaraiah Man
JGH Open.2021; 5(11): 1306. CrossRef
Inflammatory Bowel Diseases in South Asian Patients: Underappreciated and Understudied
Bharati Kochar
Inflammatory Bowel Diseases.2020; 26(12): 1943. CrossRef
Family History of Diabetes is Associated with Increased Risk of Recurrent Diabetic Ketoacidosis in Pediatric Patients
Janaki D. Vakharia, Sungeeta Agrawal, Janine Molino, Lisa Swartz Topor
Endocrine Practice.2020; 26(3): 305. CrossRef
Paediatric inflammatory bowel disease in India: a prospective multicentre study
Anshu Srivastava, Malathi Sathiyasekharan, Barath Jagadisan, Rishi Bolia, Maya Peethambaran, Geetha Mammayil, Bhaswati Acharya, Rohan Malik, Srinivas Sankaranarayanan, Vishnu Biradar, Smita Malhotra, Mathew Philip, Ujjal Poddar, Surender Kumar Yachha
European Journal of Gastroenterology & Hepatology.2020; 32(10): 1305. CrossRef

7,214 View
167 Download
18 Web of Science
18 Crossref

Inflammatory bowel diseases

Polypharmacy is a risk factor for disease flare in adult patients with ulcerative colitis: a retrospective cohort study: Jingzhou Wang, Takahiro I Nakamura, Anne G Tuskey, Brian W Behm; Intest Res 2019;17(4):496-503. Published online October 14, 2019; DOI: https://doi.org/10.5217/ir.2019.00050

Abstract PDF PubReader ePub

Background/Aims
Polypharmacy is a common clinical problem with chronic diseases that can be associated with adverse patient outcomes. The present study aimed to determine the prevalence and patient-specific characteristics associated with polypharmacy in an ulcerative colitis (UC) population and to assess the impact of polypharmacy on disease outcomes.
Methods
A retrospective chart review of patients with UC who visited a tertiary medical center outpatient clinic between 2006 and 2011 was performed. Polypharmacy was defined as major ( ≥ 5 non-UC medications) or minor (2–4 non-UC medications). UC medications were excluded in the polypharmacy grouping to minimize the confounding between disease severity and polypharmacy. Outcomes of interest include disease flare, therapy escalation, UC-related hospitalization, and surgery within 5 years of the initial visit.
Results
A total of 457 patients with UC were eligible for baseline analysis. Major polypharmacy was identified in 29.8% of patients, and minor polypharmacy was identified in 40.9% of the population. Polypharmacy at baseline was associated with advanced age (P< 0.001), female sex (P= 0.019), functional gastrointestinal (GI) disorders (P< 0.001), and psychiatric disease (P< 0.001). Over 5 years of follow-up, 265 patients remained eligible for analysis. After adjusting for age, sex, functional GI disorders, and psychiatric disease, major polypharmacy was found to be significantly associated with an increased risk of disease flare (odds ratio, 4.00; 95% confidence interval, 1.66–9.62). However, major polypharmacy was not associated with the risk of therapy escalation, hospitalization, or surgery.
Conclusions
Polypharmacy from non-inflammatory bowel disease medications was present in a substantial proportion of adult patients with UC and was associated with an increased risk of disease flare.

Citations

Citations to this article as recorded by

In vitro safety signals for potential clinical development of the anti-inflammatory pregnane X receptor agonist FKK6
Zdeněk Dvořák, Barbora Vyhlídalová, Petra Pečinková, Hao Li, Pavel Anzenbacher, Alena Špičáková, Eva Anzenbacherová, Vimanda Chow, Jiabao Liu, Henry Krause, Derek Wilson, Tibor Berés, Petr Tarkowski, Dajun Chen, Sridhar Mani
Bioorganic Chemistry.2024; 144: 107137. CrossRef
A Gastroenterologist's guide to drug interactions of small molecules for inflammatory bowel disease
Sivan Harnik, Bella Ungar, Ronen Loebstein, Shomron Ben‐Horin
United European Gastroenterology Journal.2024; 12(5): 627. CrossRef
Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study
Jeongkuk Seo, Seonok Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Ye‐Jee Kim, Byong Duk Ye
Alimentary Pharmacology & Therapeutics.2024; 60(3): 389. CrossRef
Similar Efficacy of Mesalazine in Adult and Older Adult Ulcerative Colitis Patients: Post Hoc Analysis of a Randomized Noninferiority Trial of 1600 mg vs 400 mg Tablets
Ekaterina Safroneeva, Helen Thorne, Ortrud Gerstner, Raphaël Laoun
Inflammatory Bowel Diseases.2024;[Epub] CrossRef
Severe Polypharmacy Increases Risk of Hospitalization Among Older Adults With Inflammatory Bowel Disease
Darren Drittel, William Schreiber-Stainthorp, Olivia Delau, Sakteesh V. Gurunathan, Joshua Chodosh, Dorry L. Segev, Mara McAdams-DeMarco, Seymour Katz, John Dodson, Aasma Shaukat, Adam S. Faye
American Journal of Gastroenterology.2024;[Epub] CrossRef
Factors contributing to flares of ulcerative colitis in North India- a case-control study
Vishavdeep Singh Rana, Gaurav Mahajan, Amol N. Patil, Anupam K. Singh, Vaneet Jearth, Aravind Sekar, Harjeet Singh, Atul Saroch, Usha Dutta, Vishal Sharma
BMC Gastroenterology.2023;[Epub] CrossRef
Worldwide Prevalence of Polypharmacy: A Systematic Review
Beatriz Dias Januário, Natália Silva Mafra, Humberto de Souza Silva, Isabella Monteiro Carvalho, Ana Luiza Sobreira Sena, Ana Paula Gomes Soares Pereira, Newton Santos de Faria Júnior, Helton Oliveira Campos
Current Drug Metabolism.2023; 24(8): 568. CrossRef
Deficits in Geriatric Assessment Associate With Disease Activity and Burden in Older Patients With Inflammatory Bowel Disease
Vera E.R. Asscher, Sanne N. Waars, Andrea E. van der Meulen-de Jong, Rogier J.L. Stuyt, A. Martine C. Baven-Pronk, Sander van der Marel, Rutger J. Jacobs, Jeoffrey J.L. Haans, Lennart J. Meijer, Jacqueline D. Klijnsma-Slagboom, Marijn H. Duin, Milou E.R.
Clinical Gastroenterology and Hepatology.2022; 20(5): e1006. CrossRef
Health Care Costs and Resource Utilization Among Patients With Crohn’s Disease With and Without Perianal Fistula
Grace Chen, Vasantha Pedarla, Kyle D Null, Susan E Cazzetta, Qasim Rana Khan, David A Schwartz
Inflammatory Bowel Diseases.2022; 28(6): 870. CrossRef
The 5Ms of Geriatrics in Gastroenterology: The Path to Creating Age-Friendly Care for Older Adults With Inflammatory Bowel Diseases and Cirrhosis
Bharati Kochar, Nneka N. Ufere, Christine S. Ritchie, Jennifer C. Lai
Clinical and Translational Gastroenterology.2022; 13(1): e00445. CrossRef
Polypharmacy in Patients With Inflammatory Bowel Disease
Francisco Mesonero, Cristina Fernández, Eugenia Sánchez-Rodríguez, Ana García-García Paredes, Carla Senosiain, Agustín Albillos, Antonio López-Sanromán
Journal of Clinical Gastroenterology.2022; 56(3): e189. CrossRef
Is it time to include older adults in inflammatory bowel disease trials? A call for action
Sophie Vieujean, Bénédicte Caron, Vipul Jairath, Athanase Benetos, Silvio Danese, Edouard Louis, Laurent Peyrin-Biroulet
The Lancet Healthy Longevity.2022; 3(5): e356. CrossRef
Psychiatric Disorders in Adult and Paediatric Patients With Inflammatory Bowel Diseases – A Systematic Review and Meta-Analysis
Laura Arp, Sabine Jansson, Vibeke Wewer, Johan Burisch
Journal of Crohn's and Colitis.2022; 16(12): 1933. CrossRef
Impact of isotretinoin on inflammatory bowel disease flare in patients with preexisting inflammatory bowel disease diagnosis: A cross-sectional study
Christina G. Lopez, Ruby Kwak, Lindsay McCormack, Guohai Zhou, Alexandra Charrow
Journal of the American Academy of Dermatology.2022; 87(6): 1399. CrossRef
Systematic review with meta‐analysis: dietary intake in adults with inflammatory bowel disease
Kelly Lambert, Daniel Pappas, Chiara Miglioretto, Arefeh Javadpour, Hannah Reveley, Laura Frank, Michael C. Grimm, Dorit Samocha‐Bonet, Georgina L. Hold
Alimentary Pharmacology & Therapeutics.2021; 54(6): 742. CrossRef
Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef
Frailty in inflammatory bowel diseases: an emerging concept
Bharati Kochar, Ariela R. Orkaby, Ashwin N. Ananthakrishnan, Christine S. Ritchie
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef
Prognostic Value of Terminal Ileal Inflammation in Patients with Ulcerative Colitis
Jongwook Yu, Jihye Park, Eun Ae Kang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Gut and Liver.2021; 15(6): 858. CrossRef
Investigation of the impact of commonly used medications on the oral microbiome of individuals living without major chronic conditions
Vanessa DeClercq, Jacob T. Nearing, Morgan G. I. Langille, Jonathan Jacobs
PLOS ONE.2021; 16(12): e0261032. CrossRef

7,122 View
181 Download
18 Web of Science
19 Crossref

Inflammatory bowel diseases

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice: Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi; Intest Res 2019;17(4):504-515. Published online August 23, 2019; DOI: https://doi.org/10.5217/ir.2019.00030

Abstract PDF PubReader ePub

Background/Aims
An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease.
Methods
Patients were prospectively enrolled between November 2014 and March 2017, after the launch of CT-P13 in Japan, and case report forms of patients followed for at least 4 months were analyzed as of July 2018.
Results
Of 523 patients in the analysis set, 372 remained on CT-P13 therapy, while 54 (20.2%) of 267 patients with Crohn’s disease, and 97 (37.9%) of 256 patients with ulcerative colitis were withdrawn during follow-up. A total of 144 adverse drug reactions (ADRs) were reported in 106 patients (20.3%). Infusion reaction was the most frequent ADR observed in 49 patients (9.4%). Efficacy parameters decreased immediately after the start of treatment in naïve patients to anti-tumor necrosis factor-α antibody. In the patients switched from originator infliximab for nonmedical reasons, the decreased parameters due to proceeded treatment with the originator were maintained in low ranges, and the treatment continuation rate was high with low ADR incidence. In contrast, in patients switched for medical reasons such as adverse event or loss of response, the incidence of ADRs was high. However, the efficacy parameters were improved, and the treatment continuation rate was not significantly different from that of the naïve patient group.
Conclusions
In this interim analysis, CT-P13 was comparable to the originator infliximab with respect to ADRs and efficacy, and is therefore considered to be a cost-efficient interchangeable biosimilar for Japanese patients with inflammatory bowel disease.

Citations

Citations to this article as recorded by

Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease
Tsubasa Oike, Naoki Akizue, Yuki Ohta, Hirotaka Koseki, Masaya Saito, Yuya Yokoyama, Yushi Imai, Takashi Taida, Kenichiro Okimoto, Keiko Saito, Sadahisa Ogasawara, Tomoaki Matsumura, Tomoo Nakagawa, Makoto Arai, Tatsuro Katsuno, Yoshihiro Fukuda, Yoshio K
Arab Journal of Gastroenterology.2024; 25(3): 257. CrossRef
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease
Gary R. Lichtenstein, Arif Soonasra, Mark Latymer, Sheena Singh, Brian G. Feagan
Expert Opinion on Biological Therapy.2024; 24(7): 691. CrossRef
Clinical experience of using biosimilars in Crohn’s disease and their effectiveness
Léa Sequier, Bénédicte Caron, Silvio Danese, Laurent Peyrin-Biroulet
Expert Opinion on Biological Therapy.2024; 24(10): 1145. CrossRef
Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis
Eun Soo Kim, Sung Kook Kim, Dong Il Park, Hyo Jong Kim, Yoo Jin Lee, Ja Seol Koo, Eun Sun Kim, Hyuk Yoon, Ji Hyun Lee, Ji Won Kim, Sung Jae Shin, Hyung Wook Kim, Hyun-Soo Kim, Young Sook Park, You Sun Kim, Tae Oh Kim, Jun Lee, Chang Hwan Choi, Dong Soo Ha
Journal of Clinical Gastroenterology.2023; 57(6): 601. CrossRef
Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study
Tomoe Kazama, Katsuyoshi Ando, Nobuhiro Ueno, Mikihiro Fujiya, Takahiro Ito, Atsuo Maemoto, Keisuke Ishigami, Masanori Nojima, Hiroshi Nakase, Shintaro Sagami
PLOS ONE.2023; 18(9): e0288393. CrossRef
Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies
Tsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada, Akimichi Morita, Mamitaro Ohtsuki, Yasuo Suzuki, Mamoru Watanabe, Hisashi Yamanaka, Toshifumi Hibi
Drug Safety.2023; 46(10): 991. CrossRef
Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics
Tsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada, Shiro Ohshima, Makoto Inoue, Yutaka Yoshioka, Hisashi Yamanaka
Modern Rheumatology.2022; 32(4): 718. CrossRef
Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)
Bincy Abraham, Bertus Eksteen, Khan Nedd, Hrishikesh Kale, Dipen Patel, Jennifer Stephens, Ahmed Shelbaya, Richard Chambers, Arif Soonasra
Advances in Therapy.2022; 39(5): 2109. CrossRef
Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis
Akimichi Morita, Kiyohiro Nishikawa, Fumika Yamada, Keiichi Yamanaka, Hideki Nakajima, Mamitaro Ohtsuki
The Journal of Dermatology.2022; 49(10): 957. CrossRef
Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan
Shintaro Sagami, Kiyohiro Nishikawa, Fumika Yamada, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi
Journal of Gastroenterology and Hepatology.2021; 36(8): 2091. CrossRef
Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future
Brian Godman, Mainul Haque, Santosh Kumar, Salequl Islam, Jaykaran Charan, Farhana Akter, Amanj Kurdi, Eleonora Allocati, Muhammed Abu Bakar, Sagir Abdur Rahim, Nusrat Sultana, Farzana Deeba, M. A. Halim Khan, A. B. M Muksudul Alam, Iffat Jahan, Zubair Ma
Current Medical Research and Opinion.2021; 37(9): 1529. CrossRef
Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness
Jae Hee Cheon, Seongsu Nah, Hyoun Woo Kang, Yun Jeong Lim, Sang-Hoon Lee, Sang Joon Lee, Sung Hyun Kim, Na Hyun Jung, Jeong Eun Park, Yeo Jin Lee, Da Bee Jeon, Yeon Mi Lee, Jong Min Kim, Sung-Hwan Park
Advances in Therapy.2021; 38(8): 4366. CrossRef
The Great Debate With IBD Biosimilars
Jimmy K Limdi, Francis A Farraye
Crohn's & Colitis 360.2021;[Epub] CrossRef
Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Hyo Yeop Song, Geom Seog Seo
Journal of the Korean Medical Association.2021; 64(9): 605. CrossRef
Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study
Stephanie L. Ho, Fang Niu, Suresh Pola, Fernando S. Velayos, Xian Ning, Rita L. Hui
BioDrugs.2020; 34(3): 395. CrossRef
Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies
Sang Joon Lee, KyungMin Baek, Sujin Lee, Yoon Jee Lee, Jeong Eun Park, Seul Gi Lee
BioDrugs.2020; 34(4): 513. CrossRef
Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update
Michele S. Barnhill, Joshua M. Steinberg, Joseph J. Jennings, James H. Lewis
Current Gastroenterology Reports.2020;[Epub] CrossRef

9,058 View
461 Download
16 Web of Science
17 Crossref

Colorectal neoplasia

Clinical outcomes of positive resection margin after endoscopic mucosal resection of early colon cancers: Junseok Park, Hyun Gun Kim, Shin Ok Jeong, Hoon gil Jo, Hyo Yeop Song, Jeeyeon Kim, Seri Ryu, Youngyun Cho, Hyun Jin Youn, Seong Ran Jeon, Jin-Oh Kim, Bong Min Ko, Yoon Mi Jeen, So-Young Jin; Intest Res 2019;17(4):516-526. Published online May 31, 2019; DOI: https://doi.org/10.5217/ir.2018.00169

Abstract PDF PubReader ePub

Background/Aims
When determining the subsequent management after endoscopic resection of the early colon cancer (ECC), various factors including the margin status should be considered. This study assessed the subsequent management and outcomes of ECCs according to margin status.
Methods
We examined the data of 223 ECCs treated by endoscopic mucosal resection (EMR) from 215 patients during 2004 to 2014, and all patients were followed-up at least for 2 years.
Results
According to histological analyses, the margin statuses of all lesions after EMR were as follows: 138 cases (61.9%) were negative, 65 cases (29.1%) were positive for dysplastic cells on the resection margins, and 20 cases (8.9%) were uncertain. The decision regarding subsequent management was affected not only by pathologic outcomes but also by the endoscopist’s opinion on whether complete resection was obtained. Surgery was preferred if the lesion extended to the submucosa (odds ratio [OR], 25.46; 95% confidence interval [CI], 7.09–91.42), the endoscopic resection was presumed incomplete (OR, 15.55; 95% CI, 4.28–56.56), or the lymph system was invaded (OR, 13.69; 95% CI, 1.76–106.57). Fourteen patients (6.2%) had residual or recurrent malignancies at the site of the previous ECC resection and were significantly associated with presumed incomplete endoscopic resection (OR, 4.59; 95% CI, 1.21–17.39) and submucosal invasion (OR, 5.14; 95% CI, 1.18–22.34).
Conclusions
Subsequent surgery was associated with submucosa invasion, lymphatic invasion, and cancer-positive margins. Presumed completeness of the resection may be helpful for guiding the subsequent management of patients who undergo endoscopic resection of ECC.

Citations

Citations to this article as recorded by

Long-term outcomes after endoscopic versus surgical resection of T1 colorectal carcinoma
Hyun Jin Bae, Hoyeon Ju, Han Hee Lee, Jinsu Kim, Bo-In Lee, Sung Hak Lee, Daeyoun David Won, Yoon Suk Lee, In Kyu Lee, Young-Seok Cho
Surgical Endoscopy.2023; 37(2): 1231. CrossRef
Emergence of a New Optical Marker for Colorectal Neoplasms: To What Extent Should We Accept It?
Han Hee Lee
Clinical Endoscopy.2022; 55(2): 315. CrossRef
Comparison of long-term recurrence-free survival between primary surgery and endoscopic resection followed by secondary surgery in T1 colorectal cancer
Eun Hye Oh, Nayoung Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Chang Sik Yu, Jin Cheon Kim, Jeong-Sik Byeon
Gastrointestinal Endoscopy.2021; 94(2): 394. CrossRef
Clinical outcomes of submucosal colorectal cancer diagnosed after endoscopic resection: a focus on the need for surgery
Yun Sik Choi, Wan Soo Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon
Intestinal Research.2020; 18(1): 96. CrossRef

8,127 View
170 Download
3 Web of Science
4 Crossref

Colorectal neoplasia

Parthenolide inhibits transforming growth factor β1-induced epithelial-mesenchymal transition in colorectal cancer cells: Shi Mao Zhu, Yong Ran Park, Seung Yong Seo, In Hee Kim, Soo Teik Lee, Sang Wook Kim; Intest Res 2019;17(4):527-536. Published online August 23, 2019; DOI: https://doi.org/10.5217/ir.2019.00031

Abstract PDF PubReader ePub

Background/Aims
Transforming growth factor-β1 (TGF-β1) induction of epithelial-mesenchymal transition (EMT) is one of the mechanisms by which colorectal cancer (CRC) cells acquire migratory and invasive capacities, and subsequently metastasize. Parthenolide (PT) expresses multiple anti-cancer and anti-inflammatory activities that inhibit nuclear factor κB by targeting the IκB kinase complex. In the present study, we aimed to investigate whether PT can inhibit TGF-β1-induced EMT in CRC cell lines.
Methods
HT-29 and SW480 cell lines were used in the experiment. Cell viability was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and sub-G1 analysis was measured by flow cytometry. The induction of EMT by TGF-β1 and inhibition of the process by PT was analyzed by phase contrast microscopy, wounding healing, cellular migration and invasion assays, and Western blotting.
Results
TGF-β1 inhibits HT-29 cell proliferation, but has no effect on SW480 cell proliferation; different concentrations of TGF-β1 did not induce apoptosis in HT-29 and SW480 cells. PT attenuates TGF-β1-induced elongated, fibroblast-like shape changing in cells. PT inhibits TGF-β1-induced cell migration and cell invasion. In addition, other EMT markers such as β-catenin, Vimentin, Snail, and Slug were suppressed by PT, while E-cadherin was increased by PT.
Conclusions
Our findings show that PT inhibits TGF-β1-induced EMT by suppressing the expression of the mesenchymal protein and increasing expression of the epithelial protein. These findings suggest a novel approach for CRC treatment by suppression of TGF-β1-induced EMT.

Citations

Citations to this article as recorded by

Cumin (Cuminum cyminum L.) seeds accelerates wound healing in rats: Possible molecular mechanisms
Khaled Abdul‐Aziz Ahmed, Ahmed A. J. Jabbar, Yaseen Galali, Ayman M. Al‐Qaaneh, Gökhan Akçakavak, Nur Ain Salehen, Rawaz Rizgar Hassan, Ramzi A. Mothana, Mahmood Ameen Abdulla, Omer I. Fantoukh, Sidig Hasson, Mohammed F. Hawwal
Skin Research and Technology.2024;[Epub] CrossRef
TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance
Allan M. Johansen, Steven D. Forsythe, Callum T. McGrath, Grayson Barker, Hugo Jimenez, Ravi K. Paluri, Boris C. Pasche
Clinical Cancer Research.2024; 30(17): 3676. CrossRef
Bitter taste signaling in cancer
Ana R. Costa, Ana C. Duarte, Ana R. Costa-Brito, Isabel Gonçalves, Cecília R.A. Santos
Life Sciences.2023; 315: 121363. CrossRef
Parthenolide inhibits proliferation and invasion, promotes apoptosis, and reverts the cell–cell adhesion loss through downregulation of NF‐κB pathway TNF‐α‐activated in colorectal cancer cells
Adriana S. Gehren, Waldemir F. de Souza, Annie C. M. Sousa‐Squiavinato, Diego A. A. Ramos, Bruno R. B. Pires, Eliana S. F. W. Abdelhay, Jose A. Morgado‐Diaz
Cell Biology International.2023; 47(9): 1638. CrossRef
Parthenolide repressed endometriosis induced surgically in rats: Role of PTEN/PI3Kinase/AKT/GSK-3β/β-catenin signaling in inhibition of epithelial mesenchymal transition
Soad L. Kabil, Hayam E. Rashed, Noura Mostafa Mohamed, Nisreen E. Elwany
Life Sciences.2023; 331: 122037. CrossRef
TGF-β in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer
Sumeet Singh, Vinita Gouri, Mukesh Samant
Medical Oncology.2023;[Epub] CrossRef
The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy
Tao An, Huanhuan Yin, Yanting Lu, Feng Liu
Drug Design, Development and Therapy.2022; Volume 16: 1255. CrossRef
Parthenolide reverses the epithelial to mesenchymal transition process in breast cancer by targeting TGFbeta1: In vitro and in silico studies
Hazera Binte Sufian, Julianna Maria Santos, Zeina S. Khan, Sobia Ahsan Halim, Ajmal Khan, Maliha Tabassum Munir, MD Khurshidul Zahid, Ahmed Al-Harrasi, Lauren S. Gollahon, Fazle Hussain, Shaikh Mizanoor Rahman
Life Sciences.2022; 301: 120610. CrossRef
Cinnamomum bejolghota Extract Inhibits Colorectal Cancer Cell Metastasis and TGF-β1-Induced Epithelial-Mesenchymal Transition via Smad and Non-Smad Signaling Pathway
Athicha Kittiwattanokhun, Sukanda Innajak, Etsu Tashiro, Masaya Imoto, Ramida Watanapokasin
Scientia Pharmaceutica.2022; 90(2): 30. CrossRef
Autoimmunity and Cancer—Two Sides of the Same Coin
Justyna Sakowska, Łukasz Arcimowicz, Martyna Jankowiak, Ines Papak, Aleksandra Markiewicz, Katarzyna Dziubek, Małgorzata Kurkowiak, Sachin Kote, Karolina Kaźmierczak-Siedlecka, Karol Połom, Natalia Marek-Trzonkowska, Piotr Trzonkowski
Frontiers in Immunology.2022;[Epub] CrossRef
Sesquiterpene Lactones and Cancer: New Insight into Antitumor and Anti-inflammatory Effects of Parthenolide-Derived Dimethylaminomicheliolide and Micheliolide
Yubo Dong, Xuanjin Qian, Jian Li, Ahmed Faeq Hussein
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Plants as a Source of Anticancer Agents: From Bench to Bedside
Wamidh H. Talib, Safa Daoud, Asma Ismail Mahmod, Reem Ali Hamed, Dima Awajan, Sara Feras Abuarab, Lena Hisham Odeh, Samar Khater, Lina T. Al Kury
Molecules.2022; 27(15): 4818. CrossRef
Pharmacological Targeting of Epithelial-to-Mesenchymal Transition in Colorectal Cancer
Nima Zafari, Mahla Velayati, Mohammadreza Nassiri, Majid Khazaei, Seyed Mahdi Hassanian, Gordon A. Ferns, Amir Avan
Current Pharmaceutical Design.2022; 28(28): 2298. CrossRef
The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities
Rubén Varela‐Calviño, Marta Rodríguez‐Quiroga, Patrícia Dias Carvalho, Flavia Martins, André Serra‐Roma, Lorena Vázquez‐Iglesias, María Páez de la Cadena, Sérgia Velho, Oscar J. Cordero
IUBMB Life.2021; 73(5): 761. CrossRef
Parthenolide Inhibits Angiogenesis in Esophageal Squamous Cell Carcinoma Through Suppression of VEGF

Bo Tian, Yuhang Xiao, Junliang Ma, Wei Ou, Hui Wang, Jie Wu, Jinming Tang, Baihua Zhang, Xiaojuan Liao, Desong Yang, Zhining Wu, Xu Li, Yong Zhou, Min Su, Wenxiang Wang
OncoTargets and Therapy.2020; Volume 13: 7447. CrossRef
Aniline-containing derivatives of parthenolide: Synthesis and anti-chronic lymphocytic leukaemia activity
Alex S. Quy, Xingjian Li, Louise Male, Tatjana Stankovic, Angelo Agathanggelou, John S. Fossey
Tetrahedron.2020; : 131631. CrossRef
Reversal of Epithelial–Mesenchymal Transition by Natural Anti-Inflammatory and Pro-Resolving Lipids
Chang Hoon Lee
Cancers.2019; 11(12): 1841. CrossRef

8,754 View
187 Download
19 Web of Science
17 Crossref

Functional bowel disorders

Frequency and intensity of gastrointestinal symptoms in exercisers individuals at rest and during physical exercise: an internet-based survey: Claudio Andre Barbosa de Lira, Ricardo Borges Viana, Kaylla Priscilla Mesquista, Douglas de Assis Teles Santos, Mário Hebling Campos, Marília Santos Andrade, Rodrigo Luiz Vancini; Intest Res 2019;17(4):537-545. Published online May 7, 2019; DOI: https://doi.org/10.5217/ir.2018.00162

Abstract PDF PubReader ePub

Background/Aims
Despite the evidence of a modest to high prevalence of gastrointestinal (GI) symptoms in recreational runners and endurance athletes, the frequency and intensity of GI symptoms in exercisers, but nonathletes, individuals from different modalities have been less investigated. Therefore, the present study aimed to assess the prevalence of GI symptoms in individuals that practice moderate or vigorous physical exercise, at rest and during physical exercise training session.
Methods
The sample consisted of 142 exercisers individuals (64 women and 78 men with mean age of 32.9 ± 10.7 years). Out of the 142 participants, 71 reported to perform moderate physical exercise and 71 reported to perform vigorous physical exercise. Participants were assessed by an internet-based questionnaire designed to assess the frequency and intensity (at rest and during physical exercise training session) of 18 GI symptoms.
Results
The GI symptoms most frequently reported by the respondents (during rest and physical exercise training session, respectively) were flatulence (90.8% and 69.7%), abdominal noise (77.5% and 41.5%), and eructation (73.9% and 52.1%). Overall, the frequency and intensity of symptoms were higher (P< 0.050) during rest than physical exercise training session for who perform moderate and vigorous physical exercise.
Conclusions
It can be concluded that GI symptoms in exercisers, but nonathletes, individuals are more prevalent during rest than during physical exercise training session, suggesting that moderate and vigorous physical exercise may act as a regulator of the GI tract.

Citations

Citations to this article as recorded by

The Frequency and Severity of Gastrointestinal Symptoms in Rugby Players
Sarah Chantler, Ruth Wood-Martin, Adrian Holliday, Glen Davison, Daniel R. Crabtree, Clint Readhead, Ben Jones
International Journal of Sports Medicine.2024; 45(04): 323. CrossRef
Use of Carbohydrate (CHO), Gluten-Free, and FODMAP-Free Diets to Prevent Gastrointestinal Symptoms in Endurance Athletes: A Systematic Review
Karen Montero-Carrasco, Maria Jose Arias-Tellez, Johana Soto-Sánchez
Nutrients.2024; 16(22): 3852. CrossRef
Exercise-Induced Gastrointestinal Symptoms in Endurance Sports: A Review of Pathophysiology, Symptoms, and Nutritional Management
Emanuela Ribichini, Giulia Scalese, Alessandra Cesarini, Chiara Mocci, Nadia Pallotta, Carola Severi, Enrico Stefano Corazziari
Dietetics.2023; 2(3): 289. CrossRef
Comparison of physiological and psychobiological acute responses between high intensity functional training and high intensity continuous training
Douglas A.T. Santos, Naiane S. Morais, Ricardo B. Viana, Gustavo C.T. Costa, Marilia S. Andrade, Rodrigo L. Vancini, Katja Weiss, Beat Knechtle, Claudio A.B. de Lira
Sports Medicine and Health Science.2023;[Epub] CrossRef

7,933 View
166 Download
2 Web of Science
4 Crossref

Functional bowel disorders

Is fecal calprotectin always normal in children with irritable bowel syndrome?: You Jin Choi, Su Jin Jeong; Intest Res 2019;17(4):546-553. Published online September 4, 2019; DOI: https://doi.org/10.5217/ir.2019.00009

Abstract PDF PubReader ePub

Background/Aims
Fecal calprotectin (FC) is a marker of intraluminal intestinal inflammation. Intestinal inflammation may contribute to the pathophysiology of irritable bowel syndrome (IBS). This study evaluated FC levels in children with IBS and differences in FC levels in children stratified by IBS subtype and healthy controls (HCs).
Methods
A total of 157 children with IBS and 56 HCs aged 4–16 years (119 boys, 94 girls, mean age of 9.48 years) were included in this prospective study. Children with IBS were diagnosed using the Rome III criteria and classified into 4 subtypes: IBS with constipation (IBS-C, n=37), IBS with diarrhea (IBS-D, n=54), IBS with alternating constipation and diarrhea (IBS-M, n=49), and IBS unsubtyped (IBS-U, n=17); postinfectious IBS (PI-IBS) was also considered. The FC concentration in stool samples was analyzed using an enzyme-linked immunosorbent assay. All participants answered a questionnaire regarding several demographic and clinical characteristics.
Results
Children with IBS had significantly higher levels of FC than the HCs (88.71 μg/g vs. 17.77 μg/g). Among the 4 IBS subtypes, the FC concentration was highest in children with IBS-D, followed by those with IBS-M, IBS-C, and IBS-U (169.94 μg/g vs. 45.04, 31.22, and 33.52 μg/g, respectively), and these differences were statistically significant. For PI-IBS, 90% of cases were in the IBS-D group.
Conclusions
The FC level was significantly higher in children with IBS than in HCs and differed depending on the IBS subtype, supporting the notion that IBS is a type of low-grade bowel inflammation.

Citations

Citations to this article as recorded by

Markers of Intestinal Permeability and Inflammation in Enterally Fed Children with Cerebral Palsy
Dorota Mickiewicz-Góra, Katarzyna Sznurkowska, Karolina Skonieczna-Żydecka, Arleta Drozd, Anna Borkowska, Maciej Zagierski, Joanna Troch, Agnieszka Szlagatys-Sidorkiewicz
Nutrients.2024; 16(15): 2447. CrossRef
Role of inflammation in pediatric irritable bowel syndrome
Giovanni Di Nardo, Cesare Cremon, Annamaria Staiano, Vincenzo Stanghellini, Osvaldo Borrelli, Caterina Strisciuglio, Claudio Romano, Saverio Mallardo, Elena Scarpato, Giovanni Marasco, Silvia Salvatore, Letizia Zenzeri, Enrico Felici, Licia Pensabene, Sim
Neurogastroenterology & Motility.2023;[Epub] CrossRef
The Role of Bovine Kappa-Casein Glycomacropeptide in Modulating the Microbiome and Inflammatory Responses of Irritable Bowel Syndrome
Yunyao Qu, Si Hong Park, David C. Dallas
Nutrients.2023; 15(18): 3991. CrossRef
Evaluating the Potential of Casein Glycomacropeptide in Adult Irritable Bowel Syndrome Management: A Pilot Study
Yunyao Qu, Si Hong Park, David C. Dallas
Nutrients.2023; 15(19): 4174. CrossRef
Association between body mass index and fecal calprotectin levels in children and adolescents with irritable bowel syndrome
Jun Hwan Kim, Dae Yong Yi, Yoo Min Lee, You Jin Choi, Ju Young Kim, Yong Hee Hong, Ji Young Park, Su Yeong Kim, Na Mi Lee, Sin Weon Yun, Soo Ahn Chae, In Seok Lim, Eung Sang Choi, In Sook Jeong
Medicine.2022; 101(32): e29968. CrossRef
Infantile Colic and the Subsequent Development of the Irritable Bowel Syndrome
Ju Hee Kim, Seung Won Lee, Yoowon Kwon, Eun Kyo Ha, Jaewoo An, Hye Ryeong Cha, Su Jin Jeong, Man Yong Han
Journal of Neurogastroenterology and Motility.2022; 28(4): 618. CrossRef
Irritable bowel syndrome in Indonesian adolescents
Yudianita Kesuma, Rini Sekartini, Ina S. Timan, Agnes Kurniawan, Saptawati Bardosono, Agus Firmansyah, Yvan Vandenplas
Jornal de Pediatria.2021; 97(2): 197. CrossRef
An Update on the Assessment and Management of Pediatric Abdominal Pain
Craig Friesen, Jennifer M Colombo, Amanda Deacy, Jennifer V Schurman
Pediatric Health, Medicine and Therapeutics.2021; Volume 12: 373. CrossRef
Increasing Evidence That Irritable Bowel Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis
Caterina Carco, Wayne Young, Richard B. Gearry, Nicholas J. Talley, Warren C. McNabb, Nicole C. Roy
Frontiers in Cellular and Infection Microbiology.2020;[Epub] CrossRef

9,948 View
169 Download
9 Web of Science
9 Crossref

Miscellaneous

Primary epiploic appendagitis: compared with diverticulitis and focused on obesity and recurrence: Youn I Choi, Hyun Sun Woo, Jun-Won Chung, Young Sup Shim, Kwang An Kwon, Kyoung Oh Kim, Yoon Jae Kim, Dong Kyun Park; Intest Res 2019;17(4):554-560. Published online October 14, 2019; DOI: https://doi.org/10.5217/ir.2018.00148

Abstract PDF PubReader ePub

Background/Aims
There is limited data to compare the clinical characteristics and recurrence rates between left-sided primary epiploic appendagitis (PEA) versus left-sided acute colonic diverticulitis (ACD), and right-sided PEA versus right-sided ACD, respectively.
Methods
We retrospectively reviewed the medical records and radiologic images of the patients who presented with left-sided or right-sided acute abdominal pain and had computer tomography performed at the time of presentation showing radiological signs of PEA or ACD between January 2004 and December 2014. We compared the clinical characteristics of left PEA versus left ACD and right PEA versus right ACD, respectively.
Results
Fifty-six patients (left:right = 27:29) and 308 patients (left:right = 24:284) were diagnosed with symptomatic PEA and ACD, respectively. Left-sided PEA were statistically significantly younger (50.2 ± 15.4 years vs. 62.1 ± 15.8 years, P= 0.009), more obese (body mass index [BMI]: 26.3 ± 2.9 kg/m2 vs. 22.3 ± 3.1 kg/m2 , P< 0.001), and had more tendencies with normal or mildly elevated high-sensitivity C-reactive protein (hsCRP) (1.2 ± 1.3 mg/dL vs. 8.4 ± 7.9 mg/dL, P< 0.001) than patients with left-sided ACD. The discriminative function of age, BMI and CRP between left-sided PEA versus left-sided ACD was 0.71 (cutoff: age ≤ 59 years, sensitivity of 66.7%, specificity of 77.8%), 0.83 (cutoff: BMI > 24.5 kg/m2 , sensitivity of 80.0%, specificity of 80.0%) and 0.80 (cutoff: CRP < 1.8 mg/dL, sensitivity of 72.2%, specificity of 85.7%).
Conclusions
If patients with left lower quadrant abdominal pain are less than 60 years, obese (BMI > 24.5 kg/m2 ) with or without normal to mild elevated CRP levels (CRP < 1.8 mg/dL), it might be necessary for clinicians to suspect the diagnosis of PEA rather than ACD.

Citations

Citations to this article as recorded by

Diagnosis and treatment of epiploic appendagitis in a Middle Eastern country: An observational retrospective analysis of 156 cases
Ayman El‐Menyar, Syed G. A. Naqvi, Omer Al‐Yahri, Abdelaziz MA Abusal, Abdulwahhab Al‐Shaikhli, Sadia Sajid, Husham Abdelrahman, Ahmad G. Kloub, Muhamed Ibnas, Rifat Latifi, Yasser M. R. Toble, Hassan Al‐Thani
World Journal of Surgery.2024; 48(6): 1363. CrossRef
Epiploic Adipose Tissue (EPAT) in Obese Individuals Promotes Colonic Tumorigenesis: A Novel Model for EPAT-Dependent Colorectal Cancer Progression
Rida Iftikhar, Patricia Snarski, Angelle N. King, Jenisha Ghimire, Emmanuelle Ruiz, Frank Lau, Suzana D. Savkovic
Cancers.2023; 15(3): 977. CrossRef
Recurrencia en pacientes con apendagitis epiploica: un reporte de caso
Mía Alejandra Gómez Corrales, Fabian Andrés Chávez Ecos, Jackeline Alexandra Espinoza Utani, Carlos Alberto Dávila Hernández
Revista colombiana de Gastroenterología.2023; 38(1): 94. CrossRef

7,885 View
124 Download
2 Web of Science
3 Crossref

Case Report

Colorectal neoplasia

Primary malignant melanoma without melanosis of the colon: Nam Hee Yi, Sang Heon Lee, Sang Heon Lee, Ji Hyun Kim, Sam Ryong Jee, Sang Yong Seol; Intest Res 2019;17(4):561-564. Published online August 5, 2019; DOI: https://doi.org/10.5217/ir.2019.00020

Abstract PDF PubReader ePub

Primary malignant melanoma (PMM) of the gastrointestinal tract is rare. Reported cases of PMM of the lower gastrointestinal tract typically describe anal and rectal involvement rather than colonic lesions. This report describes a rare case of a 50-year-old woman with PMM originating in the colon. The patient presented to Inje University Busan Paik Hospital with a 3-day history of blood-tinged stools. She underwent colonoscopy for a diagnosis of hematochezia. The colonoscopic examination revealed a large-sized semi-pedunculated sigmoid colon polyp with a reddish-colored mucosal surface. Endoscopic mucosal resection was performed, and the final histopathological findings were consistent with a diagnosis of malignant melanoma. Systemic work-up was performed for assessment of metastasis and to identify the primary tumor considering the high metastatic rate of gastrointestinal malignant melanoma; however, no other malignant lesion was detected. Thus, she was diagnosed with colonic PMM. She underwent laparoscopic low anterior resection and lymph node dissection and has been recurrence-free for > 2 years.

Citations

Citations to this article as recorded by

Malignant primary melanoma of the colon: a case report
Claire K Foley, Marybeth S Hughes, Charles T Hehman
Journal of Surgical Case Reports.2023;[Epub] CrossRef

6,386 View
182 Download
4 Web of Science
1 Crossref

Images of the Issue

IBD

Stroke and neck bruit in a boy with Crohn’s disease: Ryosaku Tomiyama, Akira Hokama, Erika Koga, Kohei Shimabukuro, Yuiko Oishi, Tetsuya Ohira, Atsushi Iraha, Tetsu Kinjo, Jiro Fujita; Intest Res 2019;17(4):565-566. Published online April 15, 2019; DOI: https://doi.org/10.5217/ir.2019.00019

PDF PubReader ePub

5,523 View
112 Download

First
Prev
Page of 1
Next
Last

Previous issues